Two studies led by UT Southwestern researchers shed light on the biology and potential vulnerabilities of schistosomes — parasitic flatworms that cause the little-known tropical disease schistosomiasis. The findings, published online today in Science, could change the course of this disease that kills up to 250,000 people a year.
About 240 million people around the world have schistosomiasis — mostly children in Africa, Asia, and South America in populations that represent “the poorest of the poor,” says study leader James J. Collins III, Ph.D., associate professor in UTSW’s department of pharmacology.
Most of those infected survive, but those who die often suffer organ failure or parasite-induced cancer. Symptoms can be serious enough to keep people from living productive lives, Collins says.
The parasite that causes this disease has a complicated life cycle that involves stages in both freshwater snails and mammals. Dwelling in mammalian hosts’ circulatory systems, schistosomes feed
President Donald Trump returned to the White House on Monday after announcing Thursday he’d tested positive for coronavirus and spending three nights at Walter Reed National Military Medical Center. As he battles COVID-19, Trump has been receiving a handful of different treatments for the disease, including an experimental antibody cocktail and the highly touted antiviral remdesivir.
As a 74-year-old overweight male, Trump has a heightened risk of experiencing severe complications from COVID-19, according to the CDC. Both age and obesity increase the risk of hospitalization by a factor of three. The White House has maintained a stoic optimism about his condition since diagnosis, and Trump himself has downplayed the seriousness of the novel coronavirus, tweeting Monday “don’t be afraid of Covid.”
We are both physician-scientists at the University of Virginia. We care for COVID-19 patients and conduct research to find better ways to diagnose and treat COVID-19.
Here we are sharing what physicians have learned over the past eight months treating various stages of this disease. Early in the year, there were few known treatments for people who showed severe COVID-19 symptoms apart from sustaining them on ventilators. Now, several months later, there are a handful of treatments, including drugs, that give doctors far better tools to heal patients, particularly very ill ones.
Looking across the 20 publics surveyed, majorities considered their medical treatments to rank above those of other publics globally. Views of medical treatments were often seen more favorably than achievements in other areas, including science, technology, STEM education, politics and the economy. In the U.S., however, 61% said their scientific achievements were at least above average, while more – 55% – said the same about their medical treatments. And in India, similarly sized majorities saw their country as above average or the best in the world across a number of areas. (The survey was conducted before the coronavirus outbreak reached pandemic proportions.)
Large majorities saw value from government investment in scientific research, saying that such investment is usually worthwhile for society over time. Majorities also generally considered it at least somewhat important to be a world leader in scientific research. But the share who considered their scientific achievements at least
AUSTIN, Texas, Sept. 29, 2020 /PRNewswire/ — Jurata Thin Film, a company focused on revolutionizing how biologics are shipped and stored, is bringing to market a new technology that allows biologics and vaccines to be packaged, shipped and stored at room temperature for extended periods of time. The first-of-its-kind technology enables up to 500 doses of vaccine to be placed on a single wafer-thin, 8.5″ x 11″ sheet of film, weighing one-hundredth of a pound (5g).
Known as MSI-TX Thin Film™, the technology represents a fundamental shift in biologic packaging and storage technology that removes the need for specialized storage containers and -80º C (-140º F) freezers that today are required to ship and store biologics.
MSI-TX Thin Film also removes the dependency on mass quantities of glass vials (currently in short supply) and removes virtually all distribution limitations. If the biopharma industry embraces and successfully integrates the
Researchers at the University of Alberta have discovered a novel, second mechanism of action by the antiviral drug remdesivir against SARS-CoV-2, according to findings published today in the Journal of Biological Chemistry.
The research team previously demonstrated how remdesivir inhibits the COVID-19 virus’s polymerase or replication machinery in a test tube.
Matthias Götte, chair of medical microbiology and immunology in the Faculty of Medicine & Dentistry, likened the polymerase to the engine of the virus. He said the first mechanism the team identified is like putting diesel fuel into an engine that needs regular gasoline.
“You can imagine that if you give it more and more diesel, you will go slower and slower and slower,” he said.
The newly identified mechanism is more like a roadblock, “so if you want to go from A to B with the wrong fuel and terrible road conditions, you either never reach B
The suspension of fertility treatments due to the COVID-19 pandemic has had a variety of psychological impacts on women whose treatments were cancelled, but there are several protective factors that can be fostered to help in the future, according to a new study by Jennifer Gordon and Ashley Balsom of University of Regina, Canada, published 18 September in the open-access journal PLOS ONE.
One in six reproductive-aged couples experiences infertility, and many turn to treatments such as intrauterine insemination (IUI) and in vitro fertilization (IVF), which require many in-person appointments to complete. On March 17, 2020, the American Society of Reproductive Medicine and the Canadian Fertility and Andrology Society announced their recommendations to immediately and indefinitely suspend all in-person fertility treatments in the United States and Canada due to COVID-19.
In the new study, researchers used online social media advertising to recruit 92 women from Canada and the U.S.